Literature DB >> 18959542

Degree-of-spread artefact in the New South Wales Central Cancer Registry.

Helen Barraclough1, Stephen Morrell, Maria Arcorace, Heather J McElroy, Deborah F Baker.   

Abstract

OBJECTIVE: To describe a data artefact in degree-of-spread at first presentation in the New South Wales Central Cancer Registry (NSW CCR), the only Australian cancer registry that records degree-of-spread data for all solid tumours.
METHOD: Trends in the proportions of cancer cases diagnosed annually over 1972-2004 by degree-of-spread categories of localised, regional, distant and unknown were calculated for each major cancer type.
RESULTS: Excepting breast cancer and melanoma, the proportion of localised cancer cases reported from 1993-1998 was approximately 5% lower than expected, and was mirrored by an artefactual increase in unknown degree-of-spread cases.
CONCLUSION: This artefact was caused by the introduction of the Electronic Notification System and cannot easily be remedied retrospectively. However, regional and distant categories of degree-of-spread in the NSW CCR data are reliably recorded for the 1972-2004 period. IMPLICATIONS: It is important that past and present cancer data users are notified and understand the quality issues with NSW CCR degree-of-spread data, and use it as recommended to avoid anomalous results or conclusions.

Entities:  

Mesh:

Year:  2008        PMID: 18959542     DOI: 10.1111/j.1753-6405.2008.00271.x

Source DB:  PubMed          Journal:  Aust N Z J Public Health        ISSN: 1326-0200            Impact factor:   2.939


  8 in total

1.  Surgical outcomes associated with oesophagectomy in New South Wales: an investigation of hospital volume.

Authors:  Efty P Stavrou; Garett S Smith; Deborah F Baker
Journal:  J Gastrointest Surg       Date:  2010-04-23       Impact factor: 3.452

2.  Crude probability of death for cancer patients by spread of disease in New South Wales, Australia 1985 to 2014.

Authors:  Xue Qin Yu; Paramita Dasgupta; Clare Kahn; Kou Kou; Susanna Cramb; Peter Baade
Journal:  Cancer Med       Date:  2021-05-06       Impact factor: 4.452

3.  Assessing measures of comorbidity and functional status for risk adjustment to compare hospital performance for colorectal cancer surgery: a retrospective data-linkage study.

Authors:  Timothy A Dobbins; Tim Badgery-Parker; David C Currow; Jane M Young
Journal:  BMC Med Inform Decis Mak       Date:  2015-07-15       Impact factor: 2.796

4.  The use and impact of cancer medicines in routine clinical care: methods and observations in a cohort of elderly Australians.

Authors:  Sallie-Anne Pearson; Andrea Schaffer
Journal:  BMJ Open       Date:  2014-05-02       Impact factor: 2.692

5.  Resource use, costs and quality of end-of-life care: observations in a cohort of elderly Australian cancer decedents.

Authors:  Julia M Langton; Preeyaporn Srasuebkul; Rebecca Reeve; Bonny Parkinson; Yuanyuan Gu; Nicholas A Buckley; Marion Haas; Rosalie Viney; Sallie-Anne Pearson
Journal:  Implement Sci       Date:  2015-02-26       Impact factor: 7.327

6.  Oesophagectomy rates and post-resection outcomes in patients with cancer of the oesophagus and gastro-oesophageal junction: a population-based study using linked health administrative linked data.

Authors:  Efty P Stavrou; Robyn Ward; Sallie-Anne Pearson
Journal:  BMC Health Serv Res       Date:  2012-11-08       Impact factor: 2.655

7.  Cancer survival disparities worsening by socio-economic disadvantage over the last 3 decades in new South Wales, Australia.

Authors:  Hanna E Tervonen; Sanchia Aranda; David Roder; Hui You; Richard Walton; Stephen Morrell; Deborah Baker; David C Currow
Journal:  BMC Public Health       Date:  2017-09-14       Impact factor: 3.295

8.  After accounting for competing causes of death and more advanced stage, do Aboriginal and Torres Strait Islander peoples with cancer still have worse survival? A population-based cohort study in New South Wales.

Authors:  Hanna E Tervonen; Richard Walton; Hui You; Deborah Baker; David Roder; David Currow; Sanchia Aranda
Journal:  BMC Cancer       Date:  2017-06-02       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.